Robert A Hegele

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8551269/publications.pdf

Version: 2024-02-01

779	51,516	2093	2439
papers	citations	100 h-index	197 g-index

809	809	809	44657
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. Alzheimer's and Dementia, 2023, 19, 226-243.	0.4	15
2	Familial combined hyperlipidemia is a polygenic trait. Current Opinion in Lipidology, 2022, 33, 126-132.	1.2	15
3	A Modern Approach to Dyslipidemia. Endocrine Reviews, 2022, 43, 611-653.	8.9	110
4	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification. Genetics in Medicine, 2022, 24, 293-306.	1.1	53
5	Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab. CJC Open, 2022, 4, 347-349.	0.7	4
6	Advances in the care of lipodystrophies. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 152-160.	1.2	5
7	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. Canadian Journal of Cardiology, 2022, 38, 311-319.	0.8	7
8	Effectiveness of a Novel Ï‰-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia. JAMA Network Open, 2022, 5, e2141898.	2.8	14
9	Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?. European Heart Journal, 2022, 43, 1413-1415.	1.0	9
10	Expanding the phenotypic and molecular spectrum of NFS1 â€related disorders that cause functional deficiencies in mitochondrial and cytosolic ironâ€“sulfur cluster containing enzymes. Human Mutation, 2022, 43, 305-315.	1.1	1
11	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	6.3	69
12	Web of Scienceâ€™s Citation Median Metrics Overcome the Major Constraints of the Journal Impact Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 367-371.	1.1	2
13	Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes and Endocrinology,the, 2022, 10, 142-148.	5.5	7
14	Caveolar dysfunction and lipodystrophies. European Journal of Endocrinology, 2022, 186, C1-C4.	1.9	4
15	Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins. Journal of Clinical Lipidology, 2022, 16, 155-159.	0.6	3
16	Great Chinese Famine and the Effects on Cardiometabolic Health for Future Generations. Hypertension, 2022, 79, 532-535.	1.3	3
17	Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2022, 29, 1361-1368.	0.8	20
18	Rapidly lowering triglyceride levels by plasma exchange in acute pancreatitis: What's the point?. Journal of Clinical Apheresis, 2022, 37, 194-196.	0.7	0

#	Article	IF	Citations
19	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. Advances in Therapy, 2022, 39, 1857-1870.	1.3	7
20	Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?. Current Atherosclerosis Reports, 2022, 24, 419-426.	2.0	8
21	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a). Journal of Lipid Research, 2022, 63, 100216.	2.0	4
22	Hypertriglyceridemia in young adults with a 22q11.2 microdeletion. European Journal of Endocrinology, 2022, 187, 91-99.	1.9	8
23	Lipid-Modifying Therapies and Stroke Prevention. Current Neurology and Neuroscience Reports, 2022, 22, 375-382.	2.0	7
24	Preventing cardiovascular events in patients with inflammatory arthritis: are we missing the mark?. Canadian Journal of Cardiology, 2022, , .	0.8	0
25	Safety and efficacy of therapies for chylomicronemia. Expert Review of Clinical Pharmacology, 2022, 15, 395-405.	1.3	15
26	Primary Aldosteronism in Hypertension: More Than a Factoid. Canadian Journal of Cardiology, 2021, 37, 196-198.	0.8	1
27	Simplifying Detection of Copy-Number Variations in Maturity-Onset Diabetes of the Young. Canadian Journal of Diabetes, 2021, 45, 71-77.	0.4	2
28	Liver Injury Associated With Ezetimibe Monotherapy. CJC Open, 2021, 3, 195-197.	0.7	4
29	Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia. Journal of Clinical Lipidology, 2021, 15, 79-87.	0.6	20
30	Ancestry-specific profiles of genetic determinants of severe hypertriglyceridemia. Journal of Clinical Lipidology, 2021, 15, 88-96.	0.6	6
31	Ketogenic diets, not for everyone. Journal of Clinical Lipidology, 2021, 15, 61-67.	0.6	36
32	Editorial comment: when Mendelian randomization goes astray. Current Opinion in Lipidology, 2021, 32, 79-80.	1.2	3
33	Abetalipoproteinemia Due to a Novel Splicing Variant in MTTP in 3 Siblings. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110224.	0.3	2
34	Lipoprotein and Lipid Metabolism. , 2021, , 235-278.		2
35	Clinical and Mutation Spectra of Cockayne Syndrome in India. Neurology India, 2021, 69, 362.	0.2	4
36	Human variant of scavenger receptor BI (R174C) exhibits impaired cholesterol transport functions. Journal of Lipid Research, 2021, 62, 100045.	2.0	8

#	Article	IF	Citations
37	Role of Common Genetic Variation in Lone Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2021, 14, e003179.	1.6	5
38	Genetics of hypertriglyceridemia and atherosclerosis. Current Opinion in Cardiology, 2021, 36, 264-271.	0.8	25
39	Editorial comment: hazards of interpreting genetic reports. Current Opinion in Lipidology, 2021, 32, 81-82.	1.2	2
40	Cardiac ryanodine receptor calcium release deficiency syndrome. Science Translational Medicine, 2021, 13, .	5.8	68
41	Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations. Circulation Genomic and Precision Medicine, 2021, 14, e003182.	1.6	10
42	Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype. Molecular and Cellular Biochemistry, 2021, 476, 2633-2650.	1.4	4
43	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. Journal of Clinical Lipidology, 2021, 15, 275-291.	0.6	8
44	Enrichment of loss-of-function and copy number variants in ventricular cardiomyopathy genes in â€˜loneâ€™ atrial fibrillation. Europace, 2021, 23, 844-850.	0.7	15
45	Improving reporting standards for polygenic scores in risk prediction studies. Nature, 2021, 591, 211-219.	13.7	265
46	Discussing polygenic risk with lipid clinic patients. Current Opinion in Lipidology, 2021, Publish Ahead of Print, 273-275.	1.2	4
47	Novel PPARG mutation in multiple family members with chylomicronemia. Journal of Clinical Lipidology, 2021, 15, 431-434.	0.6	3
48	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	5.5	109
49	Evaluating Polygenic Risk Scores in â€œLoneâ€•Atrial Fibrillation. CJC Open, 2021, 3, 751-757.	0.7	5
50	Lipid effects of glucagon-like peptide 1 receptor analogs. Current Opinion in Lipidology, 2021, 32, 191-199.	1.2	13
51	Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen. Frontiers in Medicine, 2021, 8, 694668.	1.2	8
52	Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2. Journal of Clinical Lipidology, 2021, 15, 653-657.	0.6	11
53	Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 685-693.	0.6	16
54	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	0.8	367

#	Article	IF	Citations
55	Comment on â€œA New Allelic Variant in the PANK2 Gene in a Patient with Incomplete HARP Syndromeâ€• Journal of Movement Disorders, 2021, 14, 254-255.	0.7	0
56	Variation in biomarker levels of metals, persistent organic pollutants, and omega-3 fatty acids in association with genetic polymorphisms among Inuit in Nunavik, Canada. Environmental Research, 2021, 200, 111393.	3.7	8
57	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	1.0	303
58	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	6.3	142
59	Contribution of rare variant associations to neurodegenerative disease presentation. Npj Genomic Medicine, 2021, 6, 80.	1.7	14
60	Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study. Lipids in Health and Disease, 2021, 20, 98.	1.2	13
61	CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins. Journal of Clinical Investigation, 2021, 131, .	3.9	12
62	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. Neurobiology of Aging, 2021, 105, 378.e1-378.e9.	1.5	8
63	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2632-2640.	1.1	42
64	What Is the Prevalence of Familial Hypercholesterolemia?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2629-2631.	1.1	6
65	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	9.4	155
66	Apolipoprotein genetic variants and hereditary amyloidosis. Current Opinion in Lipidology, 2021, 32, 132-140.	1.2	2
67	Preprint servers in lipidology. Current Opinion in Lipidology, 2021, Publish Ahead of Print, .	1.2	1
68	Integrated Analysis of the Pancreas and Islets Reveals Unexpected Findings in Human Male With Type 1 Diabetes. Journal of the Endocrine Society, 2021, 5, bvab162.	0.1	0
69	DNA sequencing in familial hypercholesterolaemia: the next generation. European Journal of Preventive Cardiology, 2021, 28, 873-874.	0.8	2
70	Lamin A/C missense variants: from discovery to functional validation. Npj Genomic Medicine, 2021, 6, 102.	1.7	6
71	Is it safe to deprescribe ezetimibe in familial hypercholesterolemia patients taking evolocumab?. CJC Open, 2021, 4, 428-431.	0.7	0
72	Dyslipidemia Management in Adults With Diabetes. Canadian Journal of Diabetes, 2020, 44, 53-60.	0.4	49

#	Article	IF	Citations
73	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	5.5	114
74	Apolipoprotein B and PNPLA3 Double Heterozygosity in a Fatherâ€“Son Pair With Advanced Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 383-385.	3.6	4
75	LDL cholesterol: lower, faster, younger?. Lancet Diabetes and Endocrinology,the, 2020, 8, 5-7.	5.5	6
76	Clinical review on triglycerides. European Heart Journal, 2020, 41, 99-109c.	1.0	286
77	Annual Report on Sex in Preclinical Studies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e1-e9.	1.1	8
78	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 2020, 311, 13-19.	0.4	21
79	Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 636-638.	0.6	5
80	Can genetic testing help in the management of dyslipidaemias?. Current Opinion in Lipidology, 2020, 31, 187-193.	1.2	9
81	A cautionary tale: Is this APOB whole-gene duplication actually pathogenic?. Journal of Clinical Lipidology, 2020, 14, 631-635.	0.6	4
82	Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2020, 76, 2736-2739.	1.2	39
83	Multisystem Progeroid Syndrome With Lipodystrophy, Cardiomyopathy, and Nephropathy Due to an LMNA p.R349W Variant. Journal of the Endocrine Society, 2020, 4, bvaa104.	0.1	7
84	Familial Chylomicronemia Syndrome With a Novel Homozygous LPL Mutation Identified in Three Siblings in Their 50s. Annals of Internal Medicine, 2020, 172, 500.	2.0	4
85	Regression of Xanthelasmas With Statin Treatment in a Normolipidemic Patient. Annals of Internal Medicine, 2020, 172, 701-702.	2.0	1
86	Genetics of Hypertriglyceridemia. Frontiers in Endocrinology, 2020, 11, 455.	1.5	100
87	Insulin's centenary: the birth of an idea. Lancet Diabetes and Endocrinology,the, 2020, 8, 971-977.	5.5	45
88	2019 George Lyman Duff Memorial Lecture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1970-1981.	1.1	16
89	Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. Circulation Genomic and Precision Medicine, 2020, 13, 515-523.	1.6	36
90	A novel homozygous variant in REN in a family presenting with classic features of disorders involving the reninâ€“angiotensin pathway, without renal tubular dysgenesis. American Journal of Medical Genetics, Part A, 2020, 182, 2284-2290.	0.7	3

#	Article	IF	Citations
91	Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists. CJC Open, 2020, 2, 625-631.	0.7	1
92	From Laundry List to Rating Scheme. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1018-1019.	1.1	0
93	Hypertension Canadaâ€™s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
94	What Is Familial Hypercholesterolemia, and Why Does It Matter?. Circulation, 2020, 141, 1760-1763.	1.6	34
95	Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia. Atherosclerosis, 2020, 304, 39-43.	0.4	3
96	Parkinson's Disease, <scp>NOTCH3</scp> Genetic Variants, and White Matter Hyperintensities. Movement Disorders, 2020, 35, 2090-2095.	2.2	18
97	Tangier disease: update for 2020. Current Opinion in Lipidology, 2020, 31, 80-84.	1.2	29
98	Delisting STAP1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 847-849.	1.1	10
99	Triglyceride-rich particles: new actors in valvular aortic stenosis. European Heart Journal, 2020, 41, 2300-2303.	1.0	3
100	Loss-of-FunctionCREB3L3Variants in Patients With Severe Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1935-1941.	1.1	19
101	Six yearsâ€™ experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias. BMC Medical Genomics, 2020, 13, 23.	0.7	52
102	Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. Journal of Clinical Lipidology, 2020, 14, 197-200.	0.6	13
103	The polygenic nature of mild-to-moderate hypertriglyceridemia. Journal of Clinical Lipidology, 2020, 14, 28-34.e2.	0.6	32
104	Experimental Therapeutics for Challenging Clinical Care of a Patient with an Extremely Rare Homozygous APOC2 Mutation. Case Reports in Endocrinology, 2020, 2020, 1-6.	0.2	4
105	Pediatric Dyslipidemiaâ€”Beyond Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2020, 36, 1362-1371.	0.8	16
106	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2020, 14, 398-413.	0.6	70
107	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	1.0	776
108	The Canadian Consensus Working Groupâ€™s Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. Contemporary Cardiology, 2020, , 137-150.	0.0	1

#	Article	IF	Citations
109	The complex molecular genetics of familial hypercholesterolaemia. Nature Reviews Cardiology, 2019, 16, 9-20.	6.1	193
110	Targeted sequencing reveals expanded genetic diversity of human transfer RNAs. RNA Biology, 2019, 16, 1574-1585.	1.5	19
111	Bioinformatic detection of copy number variation in HNF4A causing maturity onset diabetes of the young. Clinical Genetics, 2019, 96, 376-377.	1.0	2
112	Copy Number Variation in GCK in Patients With Maturity-Onset Diabetes of the Young. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3428-3436.	1.8	10
113	Can one overcome â€œunhealthy genesâ€?. Npj Genomic Medicine, 2019, 4, 24.	1.7	1
114	Ischemic Event Reduction and Triglycerides. Journal of the American College of Cardiology, 2019, 74, 1848-1849.	1.2	1
115	A tip of the CAP1 to cholesterol metabolism. European Heart Journal, 2019, 41, 253-254.	1.0	3
116	Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice. Lancet Diabetes and Endocrinology,the, 2019, 7, 880-886.	5.5	19
117	Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia. CJC Open, 2019, 1, 225-230.	0.7	10
118	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. CJC Open, 2019, 1, 190-197.	0.7	2
119	Partial LPL deletions: rare copy-number variants contributing towards severe hypertriglyceridemia. Journal of Lipid Research, 2019, 60, 1953-1958.	2.0	12
120	Research digest: observing risks and benefits of diet and supplements. Lancet Diabetes and Endocrinology,the, 2019, 7, 752.	5.5	0
121	Genetic and epigenetic study of an Alzheimerâ€™s disease family with monozygotic triplets. Brain, 2019, 142, 3375-3381.	3.7	11
122	Research digest: seeking new lipid drug targets. Lancet Diabetes and Endocrinology,the, 2019, 7, 594.	5.5	0
123	Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). American Journal of Cardiology, 2019, 124, 1876-1880.	0.7	23
124	Severe Combined Dyslipidemia With a Complex Genetic Basis. Journal of Investigative Medicine High Impact Case Reports, 2019, 7, 232470961987705.	0.3	2
125	Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis, 2019, 283, 137-142.	0.4	67
126	Lipid-Lowering Agents. Circulation Research, 2019, 124, 386-404.	2.0	124

#	Article	IF	Citations
127	Cholesterol-Lowering Agents. Circulation Research, 2019, 124, 364-385.	2.0	45
128	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. Canadian Journal of Neurological Sciences, 2019, 46, 491-498.	0.3	7
129	Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia. CJC Open, 2019, 1, 115-118.	0.7	8
130	Targeted next generation sequencing as a tool for precision medicine. BMC Medical Genomics, 2019, 12, 81.	0.7	54
131	Low LDL cholesterolâ€"Friend or foe?. Journal of Clinical Lipidology, 2019, 13, 367-373.	0.6	16
132	Clinical Utility and Practical Considerations of a Coronary Artery Disease Genetic Risk Score. CJC Open, 2019, 1, 69-75.	0.7	4
133	Atypical familial dysbetalipoproteinemia associated with high polygenic cholesterol and triglyceride scores treated with ezetimibe and evolocumab. Journal of Clinical Lipidology, 2019, 13, 411-414.	0.6	4
134	A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States. Clinical Therapeutics, 2019, 41, 426-444.	1.1	17
135	Progress in finding pathogenic DNA copy number variations in dyslipidemia. Current Opinion in Lipidology, 2019, 30, 63-70.	1.2	18
136	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society, 2019, 3, 2397-2410.	0.1	32
137	Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers. Clinical Therapeutics, 2019, 41, 2500-2516.	1.1	3
138	Editorial. Current Opinion in Lipidology, 2019, 30, 53-55.	1.2	9
139	The evolution of genetic-based risk scores for lipids and cardiovascular disease. Current Opinion in Lipidology, 2019, 30, 71-81.	1.2	49
140	Cannabis effects on lipoproteins. Current Opinion in Lipidology, 2019, 30, 140-146.	1.2	15
141	GPIHBP1 autoantibody syndrome during interferon Î²1a treatment. Journal of Clinical Lipidology, 2019, 13, 62-69.	0.6	15
142	The role of genetic testing in dyslipidaemia. Pathology, 2019, 51, 184-192.	0.3	44
143	Update on the diagnosis, treatment and management of rare genetic lipid disorders. Pathology, 2019, 51, 193-201.	0.3	14
144	Lipids and cardiovascular disease. Pathology, 2019, 51, 129-130.	0.3	5

#	Article	IF	Citations
145	Cholesterol Lowering and Prevention of Stroke. Stroke, 2019, 50, 537-541.	1.0	27
146	Severe hypertriglyceridemia is primarily polygenic. Journal of Clinical Lipidology, 2019, 13, 80-88.	0.6	136
147	Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence. Journal of Clinical Lipidology, 2019, 13, 89-99.	0.6	29
148	Complex effects of laminopathy mutations on nuclear structure and function. Clinical Genetics, 2019, 95, 199-209.	1.0	26
149	Tools for Enhancement and Quality Improvement of Peer Assessment and Clinical Care in Endocrinology and Metabolism. Journal of Clinical Densitometry, 2019, 22, 125-149.	0.5	2
150	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
151	27-OR: Simplifying Detection of Large Scale Deletions Causing MODY5. Diabetes, 2019, 68, 27-OR.	0.3	0
152	Hypertension Canadaâ€™s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
153	Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?. Canadian Journal of Cardiology, 2018, 34, 546-551.	0.8	3
154	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. Journal of Visualized Experiments, 2018, , .	0.2	17
155	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of Clinical Lipidology, 2018, 12, 920-927.e4.	0.6	97
156	Dyslipidemia. Canadian Journal of Diabetes, 2018, 42, S178-S185.	0.4	50
157	Genetic polymorphisms are associated with exposure biomarkers for metals and persistent organic pollutants among Inuit from the Inuvialuit Settlement Region, Canada. Science of the Total Environment, 2018, 634, 569-578.	3.9	8
158	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. Canadian Journal of Cardiology, 2018, 34, 532-535.	0.8	1
159	A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome. Journal of Clinical Lipidology, 2018, 12, 506-510.	0.6	10
160	Learning From Patients With Ultrarare Conditions. Journal of the American College of Cardiology, 2018, 71, 289-291.	1.2	3
161	Secondary causes of chylomicronemia: defining the underside of the iceberg. Journal of Internal Medicine, 2018, 283, 405-407.	2.7	3
162	Whole genome sequencing in the clinic: empowerment or too much information?. Cmaj, 2018, 190, E124-E125.	0.9	17

#	Article	IF	Citations
163	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. Canadian Journal of Cardiology, 2018, 34, 595-604.	0.8	56
164	Nutraceuticals in endocrine disorders. Nature Reviews Endocrinology, 2018, 14, 68-70.	4.3	7
165	Role of DNA copy number variation in dyslipidemias. Current Opinion in Lipidology, 2018, 29, 125-132.	1.2	33
166	Polygenic influences on dyslipidemias. Current Opinion in Lipidology, 2018, 29, 133-143.	1.2	51
167	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
168	Complex genetic architecture in severe hypobetalipoproteinemia. Lipids in Health and Disease, 2018, 17, 48.	1.2	14
169	Cover Image, Volume 177B, Number 1, January 2018. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, i.	1.1	0
170	A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1005-1014.	1.8	47
171	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	1.5	47
172	OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 75-85.	1.1	12
173	Food Effect on Rosuvastatin Disposition and Lowâ€Density Lipoprotein Cholesterol. Clinical Pharmacology and Therapeutics, 2018, 104, 525-533.	2.3	9
174	The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. Journal of Clinical Lipidology, 2018, 12, 152-161.	0.6	48
175	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nature Reviews Cardiology, 2018, 15, 9-19.	6.1	105
176	A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation. Endocrine Pathology, 2018, 29, 374-379.	5.2	6
177	Whole-exome sequencing identifies a novel IHH insertion in an Ontario family with brachydactyly type A1. SAGE Open Medical Case Reports, 2018, 6, 2050313X1881871.	0.2	4
178	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	0.8	105
179	Multiple Symmetric Lipomatosis (Madelung Disease) in a Large Canadian Family With the Mitochondrial MTTK c.8344A>G Variant. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961880286.	0.3	12
180	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. Atherosclerosis, 2018, 277, 419-424.	0.4	18

#	Article	IF	Citations
181	Unusual genetic variants associated with hypercholesterolemia in Argentina. Atherosclerosis, 2018, 277, 256-261.	0.4	22
182	Reporting Sex and Sex Differences in Preclinical Studies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e171-e184.	1.1	13
183	Recent Highlights of ATVB. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e185-e197.	1.1	3
184	ClinVar database of global familial hypercholesterolemiaâ€associated DNA variants. Human Mutation, 2018, 39, 1631-1640.	1.1	84
185	Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. Journal of Lipid Research, 2018, 59, 2421-2435.	2.0	49
186	Response by Daugherty et al to Letter Regarding Article, â€œConsideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies: A Statement From the Arteriosclerosis, Thrombosis, and Vascular Biology Councilâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e101-e102.	1.1	3
187	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	0.8	62
188	PCSK9 inhibitors in familial hypercholesterolemia:ÂWhat is the evidence?. Journal of Clinical Lipidology, 2018, 12, 1106-1108.	0.6	5
189	Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 959-961.	0.8	4
190	Copy-number variation (CNVs) in Hypertriglyceridemia Patients. Atherosclerosis Supplements, 2018, 32, 50.	1.2	0
191	Update on the Familial Hypercholesterolemia Canada (FH Canada) Registry. Atherosclerosis Supplements, 2018, 32, 51-52.	1.2	0
192	To PLEX or not to PLEX: Managing Hypertriglyceridemia-associated Pancreatitis. Atherosclerosis Supplements, 2018, 32, 148.	1.2	0
193	LDL-C Therapeutic Target Attainment in Patients with Homozygous Familial Hypercholesterolemia treated with Lomitapide. Atherosclerosis Supplements, 2018, 32, 153-154.	1.2	0
194	Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. Journal of Clinical Lipidology, 2018, 12, 1146-1150.	0.6	4
195	Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1316-1324.	0.8	34
196	Connecting Extreme Ends of the Spectrum: Ultra-rare Androgen Receptor Mutations in Metabolic Phenotypes. Atherosclerosis Supplements, 2018, 32, 81.	1.2	0
197	The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology, 2018, 72, 314-329.	1.2	162
198	A De Novo POLD1 Mutation Associated With Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome in a Family With Werner Syndrome. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961878677.	0.3	10

#	Article	IF	Citations
199	Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. Lipids in Health and Disease, 2018, 17, 8.	1.2	8
200	Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of Highâ€Ðensity Lipoprotein Cholesterol. Journal of the American Heart Association, 2018, 7, e009545.	1.6	25
201	Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia. Journal of Lipid Research, 2018, 59, 1529-1535.	2.0	22
202	Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. Journal of Clinical Lipidology, 2017, 11, 294-296.	0.6	7
203	Estrogen-associated severe hypertriglyceridemia with pancreatitis. Journal of Clinical Lipidology, 2017, 11, 297-300.	0.6	21
204	Genetics for the Identification of Lipid Targets Beyond PCSK9. Canadian Journal of Cardiology, 2017, 33, 334-342.	0.8	8
205	Functional foods and dietary supplements for the management of dyslipidaemia. Nature Reviews Endocrinology, 2017, 13, 278-288.	4.3	154
206	Barriers to the Implementation of Lipoprotein Apheresis in Canada. Canadian Journal of Cardiology, 2017, 33, 409-411.	0.8	9
207	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
208	Clinical utility gene card for: Sitosterolaemia. European Journal of Human Genetics, 2017, 25, 512-512.	1.4	14
209	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	1.0	2,292
210	Complexity of mechanisms among human proprotein convertase subtilisinâ€“kexin type 9 variants. Current Opinion in Lipidology, 2017, 28, 161-169.	1.2	57
211	PCSK9 inhibitors: smooth sailing or a little turbulence ahead?. Lancet Diabetes and Endocrinology,the, 2017, 5, 490-492.	5.5	1
212	Insulin affordability. Lancet Diabetes and Endocrinology,the, 2017, 5, 324.	5.5	4
213	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. Cell Reports, 2017, 19, 1456-1466.	2.9	36
214	Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders. Expert Opinion on Orphan Drugs, 2017, 5, 411-420.	0.5	1
215	Recent advances in genetic testing for familial hypercholesterolemia. Expert Review of Molecular Diagnostics, 2017, 17, 641-651.	1.5	53
216	Genetics of Triglycerides and the Risk of Atherosclerosis. Current Atherosclerosis Reports, 2017, 19, 31.	2.0	89

#	Article	IF	Citations
217	Clinical utility gene card for: Tangier disease. European Journal of Human Genetics, 2017, 25, e1-e3.	1.4	7
218	Lomitapide for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1261-1268.	0.9	47
219	Treatment of Severe Hypercholesterolemia in a Woman With Advanced Primary Sclerosing Cholangitis. JAMA Cardiology, 2017, 2, 575.	3.0	4
220	Seeking â€˜meta guidelinesâ€™ for lipids. European Journal of Preventive Cardiology, 2017, 24, 72-75.	0.8	1
221	A truncating mutation in CEP55 is the likely cause of MARCH, a novel syndrome affecting neuronal mitosis. Journal of Medical Genetics, 2017, 54, 490-501.	1.5	45
222	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Canadian Journal of Neurological Sciences, 2017, 44, 196-202.	0.3	72
223	Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Molecular Pharmaceutics, 2017, 14, 310-318.	2.3	53
224	KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection. American Journal of Medical Genetics, Part A, 2017, 173, 183-189.	0.7	15
225	PCSK9 inhibition and diabetes: turning to Mendel for clues. Lancet Diabetes and Endocrinology,the, 2017, 5, 78-79.	5.5	3
226	Recent Advances in the Genetics of Atherothrombotic Disease and Its Determinants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e158-e166.	1.1	7
227	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. Journal of Lipid Research, 2017, 58, 2188-2196.	2.0	32
228	Genetic studies in definite/probable FH in Argentina. Atherosclerosis, 2017, 263, e62.	0.4	0
229	Severe hypertriglycerideamia related to a novel mutation in TRIB1 and a known variant in APOA5. Atherosclerosis, 2017, 263, e230.	0.4	0
230	ARHGEF28 p.Lys280Metfs40Ter in an amyotrophic lateral sclerosis family with a C9orf72 expansion. Neurology: Genetics, 2017, 3, e190.	0.9	6
231	CETP Inhibitors â€” A New Inning?. New England Journal of Medicine, 2017, 377, 1284-1285.	13.9	23
232	Severe familial hypercholesterolaemia in two brothers with three heterozygous coding mutations in LDLR. Atherosclerosis, 2017, 263, e230.	0.4	0
233	Use of next-generation sequencing to detect copy number variations in the molecular diagnosis of familial hypercholesterolemia. Atherosclerosis, 2017, 263, e236.	0.4	0
234	Polygenic determinants in extremes of high-density lipoprotein cholesterol. Journal of Lipid Research, 2017, 58, 2162-2170.	2.0	49

#	Article	IF	Citations
235	Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia. Journal of Lipid Research, 2017, 58, 2202-2209.	2.0	65
236	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
237	Polygenic Risk for Hypertriglyceridemia Can Mimic a Major Monogenic Mutation. Annals of Internal Medicine, 2017, 167, 360.	2.0	18
238	Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels. Journal of Molecular Diagnostics, 2017, 19, 905-920.	1.2	104
239	Statin therapy: time for a precision medicine approach?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 187-192.	0.4	1
240	Familial hypercholesterolaemia. Nature Reviews Disease Primers, 2017, 3, 17093.	18.1	315
241	PCSK9: Regulation and Target for Drug Development for Dyslipidemia. Annual Review of Pharmacology and Toxicology, 2017, 57, 223-244.	4.2	58
242	Fatty liver in a non-obese patient. Paediatrics and Child Health, 2017, 22, 59-60.	0.3	1
243	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). Journal of Alzheimer's Disease, 2017, 59, 707-721.	1.2	54
244	A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1454-1457.	1.8	35
245	Identification of a novel synaptic protein, TMTC3, involved in periventricular nodular heterotopia with intellectual disability and epilepsy. Human Molecular Genetics, 2017, 26, 4278-4289.	1.4	36
246	Combined hyperlipidemia. Current Opinion in Lipidology, 2016, 27, 131-140.	1.2	64
247	Whole-genome sequencing in French Canadians from Quebec. Human Genetics, 2016, 135, 1213-1221.	1.8	16
248	Rare Genetic Variants and High-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, e53-5.	1.1	11
249	New oral agents for treating dyslipidemia. Current Opinion in Lipidology, 2016, 27, 579-584.	1.2	8
250	Genetics of Lipid and Lipoprotein Disorders and Traits. Current Genetic Medicine Reports, 2016, 4, 130-141.	1.9	61
251	The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration. Npj Genomic Medicine, 2016, 1, 16032.	1.7	26
252	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. Atherosclerosis, 2016, 250, 63-68.	0.4	11

#	Article	IF	Citations
253	Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?. Canadian Journal of Cardiology, 2016, 32, 598-602.	0.8	2
254	Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes. Journal of Lipid Research, 2016, 57, 1601-1607.	2.0	20
255	Familial partial lipodystrophy presenting as metabolic syndrome. Journal of Clinical Lipidology, 2016, 10, 1488-1491.	0.6	22
256	Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2439-2445.	1.1	174
257	Genetic Confirmation Rate in Clinically Suspected Maturity-Onset Diabetes of the Young. Canadian Journal of Diabetes, 2016, 40, 555-560.	0.4	17
258	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775
259	The Sum of Its Parts: The Polygenic Basis of Coronary Artery Disease. Canadian Journal of Cardiology, 2016, 32, 1372-1374.	0.8	1
260	Lomitapide for the treatment of hypertriglyceridemia. Expert Opinion on Investigational Drugs, 2016, 25, 1457-1463.	1.9	20
261	Complying With the National Institutes of Health Guidelines and Principles for Rigor and Reproducibility. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1303-1304.	1.1	12
262	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes, 2016, 65, 1767-1778.	0.3	155
263	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes and Endocrinology,the, 2016, 4, 850-861.	5.5	329
264	A tale of 2 cousins: An atypical and a typical case of abetalipoproteinemia. Journal of Clinical Lipidology, 2016, 10, 1030-1034.	0.6	11
265	A novel ICK mutation causes ciliary disruption and lethal endocrine-cerebro-osteodysplasia syndrome. Cilia, 2016, 5, 8.	1.8	37
266	Integrated Measure for Atherogenic Lipoproteins in the Modern Era. Journal of the American College of Cardiology, 2016, 67, 202-204.	1.2	4
267	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology, 2016, 32, S35-S65.	0.8	194
268	Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia â^—. Journal of the American College of Cardiology, 2016, 67, 1286-1288.	1.2	7
269	Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?. Current Atherosclerosis Reports, 2016, 18, 24.	2.0	20
270	Proprietary Considerations in the Use of Cardiovascular Genetic Data. Canadian Journal of Cardiology, 2016, 32, 1297-1299.	0.8	2

#	Article	IF	Citations
271	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
272	Statin Safety in Chinese: A Population-Based Study of Older Adults. PLoS ONE, 2016, 11, e0150990.	1.1	17
273	Matching Two Independent Cohorts ValidatesDPH1as a Gene Responsible for Autosomal Recessive Intellectual Disability with Short Stature, Craniofacial, and Ectodermal Anomalies. Human Mutation, 2015, 36, 1015-1019.	1.1	32
274	MG-107â€…Congenital sucrase-isomaltase deficiency: Identification of the common inuit founder mutation. Journal of Medical Genetics, 2015, 52, A1.3-A2.	1.5	0
275	Severe Hypertriglyceridemia due to a novel p.Q240H mutation in the Lipoprotein Lipase gene. Lipids in Health and Disease, 2015, 14, 102.	1.2	9
276	MG-137â€…Autosomal recessive disorders are common in the old order amish population of southwestern ontario. Journal of Medical Genetics, 2015, 52, A10.1-A10.	1.5	0
277	Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology, 2015, 26, 484-491.	1.2	35
278	Validation of volumetric and singleâ€slice MRI adipose analysis using a novel fully automated segmentation method. Journal of Magnetic Resonance Imaging, 2015, 41, 233-241.	1.9	46
279	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2015, 110, S773.	0.2	0
280	Chylomicronaemiaâ€”current diagnosis and future therapies. Nature Reviews Endocrinology, 2015, 11, 352-362.	4.3	242
281	Statin-associated muscle symptoms: impact on statin therapyâ€”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	1.0	1,024
282	Lipid Management in Diabetes with a Focus on Emerging Therapies. Canadian Journal of Diabetes, 2015, 39, S183-S190.	0.4	8
283	Autosomal-Recessive Intellectual Disability with Cerebellar Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter Gene SLC39A8. American Journal of Human Genetics, 2015, 97, 886-893.	2.6	171
284	Hypertriglyceridemia in the Genomic Era: A New Paradigm. Endocrine Reviews, 2015, 36, 131-147.	8.9	118
285	A homozygousPMS2founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. Journal of Medical Genetics, 2015, 52, 348-352.	1.5	30
286	Loss-of-Function Mutations inABCA1and Enhanced Î²-Cell Secretory Capacity in Young Adults. Diabetes, 2015, 64, 193-199.	0.3	32
287	Incident Diabetes With Statins: Biology, Artifact, or Both?. Canadian Journal of Cardiology, 2015, 31, 963-965.	0.8	4
288	Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB) â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	1.4	10

#	Article	IF	Citations
289	Statin Intolerance. Circulation, 2015, 131, e389-91.	1.6	53
290	An siRNA-based functional genomics screen for theÂidentification of regulators of ciliogenesis and ciliopathyÂgenes. Nature Cell Biology, 2015, 17, 1074-1087.	4.6	215
291	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 3620-3630.	1.1	66
292	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
293	Congenital sucraseâ€“isomaltase deficiency: identification of a common Inuit founder mutation. Cmaj, 2015, 187, 102-107.	0.9	31
294	Common Low-Density Lipoprotein Receptor p.G116S Variant Has a Large Effect on Plasma Low-Density Lipoprotein Cholesterol in Circumpolar Inuit Populations. Circulation: Cardiovascular Genetics, 2015, 8, 100-105.	5.1	14
295	Ezetimibe. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, e13-5.	1.1	15
296	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2015, 16, 1255-1262.	0.9	15
297	Targeted next-generation sequencing in monogenic dyslipidemias. Current Opinion in Lipidology, 2015, 26, 103-113.	1.2	91
298	HDL re-examined. Current Opinion in Lipidology, 2015, 26, 127-132.	1.2	35
299	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. Human Molecular Genetics, 2015, 24, 3582-3594.	1.4	53
300	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	1.0	644
301	Nonstatin Low-Density Lipoproteinâ€“Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From ATVB Council. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2269-2280.	1.1	58
302	Clinical utility gene card for: Abetalipoproteinaemia â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	1.4	8
303	Old gene, new phenotype: mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental disorder, no exostoses. Journal of Medical Genetics, 2015, 52, 666-675.	1.5	28
304	Antisenses working overtime in lipids. Nature Reviews Endocrinology, 2015, 11, 574-576.	4.3	2
305	Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide. Journal of Biological Chemistry, 2015, 290, 25863-25875.	1.6	68
306	The Genetics of Cardiovascular Disease in Canadian and International Aboriginal Populations. Canadian Journal of Cardiology, 2015, 31, 1094-1115.	0.8	9

#	Article	IF	Citations
307	Finding the Therapeutic Sweet Spot. Circulation: Cardiovascular Genetics, 2015, 8, 637-639.	5.1	4
308	G-Protein Estrogen Receptor as a Regulator of Low-Density Lipoprotein Cholesterol Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 213-221.	1.1	45
309	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518, 102-106.	13.7	581
310	Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries. Clinical Chemistry, 2015, 61, 231-238.	1.5	166
311	Simple genetics language as source of miscommunication between genetics researchers and potential research participants in informed consent documents. Public Understanding of Science, 2015, 24, 751-766.	1.6	11
312	The New Dyslipidemia Guidelines: What Is the Debate?. Canadian Journal of Cardiology, 2015, 31, 605-612.	0.8	46
313	A novel MC4R mutation associated with childhood-onset obesity: A case report. Paediatrics and Child Health, 2014, 19, 515-518.	0.3	35
314	LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias. Journal of Lipid Research, 2014, 55, 765-772.	2.0	108
315	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	1.0	835
316	Gene Therapy for Hypercholesterolemia. Circulation Research, 2014, 115, 542-545.	2.0	5
317	Linkage analysis and exome sequencing identify a novel mutation in <scp>KCTD</scp>7 in patients with progressive myoclonus epilepsy with ataxia. Epilepsia, 2014, 55, e106-11.	2.6	26
318	Exome Sequencing as a Diagnostic Tool for Pediatricâ€Onset Ataxia. Human Mutation, 2014, 35, 45-49.	1.1	91
319	Doctor My Eyes: A Statin-Cataract Connection?. Canadian Journal of Cardiology, 2014, 30, 1508-1510.	0.8	2
320	A Novel LIPE Nonsense Mutation Found Using Exome Sequencing in Siblings With Late-Onset Familial PartialÂLipodystrophy. Canadian Journal of Cardiology, 2014, 30, 1649-1654.	0.8	58
321	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. Muscle and Nerve, 2014, 49, 928-930.	1.0	13
322	Canadian Cardiovascular Society Position Statement onÂFamilial Hypercholesterolemia. Canadian Journal of Cardiology, 2014, 30, 1471-1481.	0.8	93
323	Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Human Molecular Genetics, 2014, 23, 5570-5578.	1.4	21
324	Severe Hypertriglyceridemia With Pancreatitis. JAMA Internal Medicine, 2014, 174, 443.	2.6	97

#	Article	IF	Citations
325	Progression to Hepatitis and Fibrosis Secondary to Lomitapide Useâ€"Reply. JAMA Internal Medicine, 2014, 174, 1522.	2.6	3
326	Progress in genetics of plasma lipids. Current Opinion in Lipidology, 2014, 25, 99-101.	1.2	1
327	A common hypofunctional genetic variant of <scp>GPER</scp> is associated with increased blood pressure in women. British Journal of Clinical Pharmacology, 2014, 78, 1441-1452.	1.1	35
328	Sequencing: The Next Generationâ€"What Is the Role of Whole-Exome Sequencing in the Diagnosis of Familial Cardiovascular Diseases?. Canadian Journal of Cardiology, 2014, 30, 152-154.	0.8	6
329	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. Canadian Journal of Cardiology, 2014, 30, 377-380.	0.8	27
330	Is Plant-Based Cardioprotection Evidence-Based?. Canadian Journal of Cardiology, 2014, 30, 1142-1144.	0.8	0
331	Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. Journal of Inherited Metabolic Disease, 2014, 37, 333-339.	1.7	154
332	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
333	Pharmacogenomics, Lipid Disorders, and Treatment Options. Clinical Pharmacology and Therapeutics, 2014, 96, 36-47.	2.3	26
334	Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. Human Molecular Genetics, 2014, 23, 2498-2510.	1.4	28
335	The Effect of Infrequent Low-Dose Rosuvastatin on the LipidÂProfile. Canadian Journal of Cardiology, 2014, 30, 1392-1395.	0.8	0
336	Exome sequencing identifies <scp>NFS</scp>1 deficiency in a novel Feâ€S cluster disease, infantile mitochondrial complex <scp>II</scp>/<scp>III</scp> deficiency. Molecular Genetics & Genomic Medicine, 2014, 2, 73-80.	0.6	53
337	Whole exome sequencing of familial hypercholesterolaemia patients negative forLDLR/APOB/PCSK9mutations. Journal of Medical Genetics, 2014, 51, 537-544.	1.5	104
338	Exome Sequencing: New Insights into Lipoprotein Disorders. Current Cardiology Reports, 2014, 16, 507.	1.3	17
339	Mining the genome for lipid genes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1993-2009.	1.8	35
340	Treatment of severe hypertriglyceridaemia â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2014, 2, 860-861.	5.5	2
341	Inducing thyrotoxicosis in the liver to treat raised cholesterol. Lancet Diabetes and Endocrinology,the, 2014, 2, 438-439.	5.5	0
342	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	5.5	473

#	Article	IF	Citations
343	N-of-1 (Single-Patient) Trials for Statin-Related Myalgia. Annals of Internal Medicine, 2014, 160, 301-310.	2.0	106
344	Disorders of Lipoprotein Metabolism. , 2014, , 671-689.		4
345	Omega-3 fatty acids, polymorphisms and lipid related cardiovascular disease risk factors in the Inuit population. Nutrition and Metabolism, 2013, 10, 26.	1.3	19
346	Intellectual disability associated with a homozygous missense mutation in THOC6. Orphanet Journal of Rare Diseases, 2013, 8, 62.	1.2	48
347	Lipoprotein and Lipid Metabolism. , 2013, , 1-33.		4
348	Homozygous Lamin A/C familial lipodystrophy R482Q mutation in autosomal recessive Emery Dreifuss muscular dystrophy. Neuromuscular Disorders, 2013, 23, 265-268.	0.3	23
349	Genetics 101 for Cardiologists: Rare Genetic Variants and Monogenic Cardiovascular Disease. Canadian Journal of Cardiology, 2013, 29, 18-22.	0.8	12
350	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. Canadian Journal of Cardiology, 2013, 29, 1553-1568.	0.8	153
351	Dyslipidemia. Canadian Journal of Diabetes, 2013, 37, S110-S116.	0.4	15
352	DyslipidÃ©mie. Canadian Journal of Diabetes, 2013, 37, S484-S491.	0.4	1
353	Western Database of Lipid Variants (WDLV): A Catalogue of Genetic Variants in Monogenic Dyslipidemias. Canadian Journal of Cardiology, 2013, 29, 934-939.	0.8	22
354	A mutation in the serine protease TMPRSS4 in a novel pediatric neurodegenerative disorder. Orphanet Journal of Rare Diseases, 2013, 8, 126.	1.2	8
355	Genetics 100 for Cardiologists: Basics of Genome-Wide Association Studies. Canadian Journal of Cardiology, 2013, 29, 10-17.	0.8	31
356	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	6.3	624
357	Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 444-451.	1.1	31
358	HDLâ€"is it too big to fail?. Nature Reviews Endocrinology, 2013, 9, 308-312.	4.3	26
359	Using Mendelian randomization to determine causative factors in cardiovascular disease. Journal of Internal Medicine, 2013, 273, 44-47.	2.7	24
360	Incremental Lowering of Low-Density Lipoprotein Cholesterol With Ezetimibe 20 mg vs 10 mg Daily in Patients Receiving Concomitant Statin Therapy. Canadian Journal of Cardiology, 2013, 29, 1395-1399.	0.8	4

#	Article	IF	Citations
361	Recessive TRAPPC11 Mutations Cause a Disease Spectrum of Limb Girdle Muscular Dystrophy and Myopathy with Movement Disorder and Intellectual Disability. American Journal of Human Genetics, 2013, 93, 181-190.	2.6	98
362	APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis, 2013, 231, 218-222.	0.4	84
363	HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature. Journal of Clinical Lipidology, 2013, 7, 169-173.	0.6	16
364	Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients. Canadian Journal of Cardiology, 2013, 29, 418-422.	0.8	10
365	Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin. Canadian Journal of Cardiology, 2013, 29, 915-919.	0.8	10
366	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
367	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2013, 29, 151-167.	0.8	680
368	Genetic Determinants of â€œCognitive Impairment, No Dementiaâ€• Journal of Alzheimer's Disease, 2013, 33, 831-840.	1.2	10
369	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
370	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. Journal of Lipid Research, 2013, 54, 1980-1987.	2.0	7
371	Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circulation: Cardiovascular Genetics, 2013, 6, 400-408.	5.1	168
372	Apolipoprotein C-III. Circulation Research, 2013, 112, 1405-1408.	2.0	59
373	Editorial comment. Current Opinion in Lipidology, 2013, 24, 109-110.	1.2	0
374	Infantile Sialic Acid Storage Disease: Two Unrelated Inuit Cases Homozygous for a Common Novel SLC17A5 Mutation. JIMD Reports, 2013, 12, 79-84.	0.7	6
375	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opinion on Investigational Drugs, 2013, 22, 1411-1423.	1.9	19
376	Geneâ€“diet interactions on plasma lipid levels in the Inuit population. British Journal of Nutrition, 2013, 109, 953-961.	1.2	54
377	Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population. PLoS ONE, 2013, 8, e66808.	1.1	57
378	Hypertriglyceridemia. Nutrients, 2013, 5, 981-1001.	1.7	108

#	Article	IF	Citations
379	The Metabolic Syndrome. , 2013, , 1006-1016.		4
380	Activation of Peroxisome Proliferator-Activated Receptor Î´ Inhibits Human Macrophage Foam Cell Formation and the Inflammatory Response Induced by Very Low-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2919-2928.	1.1	47
381	Lipoprotein(a). Current Opinion in Lipidology, 2012, 23, 133-140.	1.2	99
382	Genetics and molecular biology. Current Opinion in Lipidology, 2012, 23, 83-84.	1.2	0
383	Clinical utility gene card for: Abetalipoproteinaemia. European Journal of Human Genetics, 2012, 20, 1-3.	1.4	37
384	Severe Hypertriglyceridemia in Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2589-2596.	1.8	147
385	The Oxysterol 24 (S) ,25â€Epoxycholesterol Attenuates Human Smooth Muscleâ€“Derived Foam Cell Formation Via Reduced Lowâ€Density Lipoprotein Uptake and Enhanced Cholesterol Efflux. Journal of the American Heart Association, 2012, 1, e000810.	1.6	23
386	Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARÎ³ deficiency. Journal of Lipid Research, 2012, 53, 1968-1978.	2.0	18
387	Linking Diabetes With Oxidative Stress, Adipokines, and Impaired Endothelial Precursor Cell Function. Canadian Journal of Cardiology, 2012, 28, 629-630.	0.8	10
388	Niacin: another look at an underutilized lipid-lowering medication. Nature Reviews Endocrinology, 2012, 8, 517-528.	4.3	41
389	Allelic and phenotypic spectrum of plasma triglycerides. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 833-842.	1.2	43
390	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
391	Excess of Rare Variants in Nonâ€“Genome-Wide Association Study Candidate Genes in Patients With Hypertriglyceridemia. Circulation: Cardiovascular Genetics, 2012, 5, 66-72.	5.1	79
392	BRCA2 Variants and cardiovascular disease in a multi-ethnic study. BMC Medical Genetics, 2012, 13, 56.	2.1	13
393	Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB). European Journal of Human Genetics, 2012, 20, 3-3.	1.4	14
394	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 2012, 91, 823-838.	2.6	227
395	The application of gene therapy in lipid disorders: where are we now?. Clinical Lipidology, 2012, 7, 419-429.	0.4	1
396	Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Design, Development and Therapy, 2012, 6, 251.	2.0	11

#	Article	IF	Citations
397	Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis. Case Reports in Gastroenterology, 2012, 6, 429-437.	0.3	9
398	A shared founder mutation underlies restrictive dermopathy in Old Colony (Dutchâ€German) Mennonite and Hutterite patients in North America. American Journal of Medical Genetics, Part A, 2012, 158A, 1229-1232.	0.7	14
399	The Complex Genetic Basis of Plasma Triglycerides. Current Atherosclerosis Reports, 2012, 14, 227-234.	2.0	35
400	Transient Infantile Hypertriglyceridemia, Fatty Liver, and Hepatic Fibrosis Caused by Mutated GPD1, Encoding Glycerol-3-Phosphate Dehydrogenase 1. American Journal of Human Genetics, 2012, 90, 49-60.	2.6	74
401	Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci. American Journal of Human Genetics, 2012, 90, 410-425.	2.6	239
402	CETP Inhibitors: Will They Live up to Their Promise?. Current Cardiovascular Risk Reports, 2012, 6, 4-11.	0.8	1
403	Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations. PLoS ONE, 2012, 7, e50198.	1.1	40
404	A novel mutation of apolipoprotein B in a French Canadian family with homozygous hypobetalipoproteinemia. Journal of Clinical Lipidology, 2011, 5, 414-417.	0.6	5
405	Clinical Implications of Direct-to-Consumer Genetic Testing for Cardiovascular Disease Risk. Canadian Journal of Cardiology, 2011, 27, 682-684.	0.8	4
406	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
407	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology, 2011, 27, 635-662.	0.8	160
408	Transcriptional Profiling of Endocrine Cerebro-Osteodysplasia Using Microarray and Next-Generation Sequencing. PLoS ONE, 2011, 6, e25400.	1.1	10
409	Genetic bases of hypertriglyceridemic phenotypes. Current Opinion in Lipidology, 2011, 22, 247-253.	1.2	108
410	Bias due to selection of rare variants using frequency in controls. Nature Genetics, 2011, 43, 394-395.	9.4	5
411	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 2011, 88, 6-18.	2.6	122
412	TMEM237 Is Mutated in Individuals with a Joubert Syndrome Related Disorder and Expands the Role of the TMEM Family at the Ciliary Transition Zone. American Journal of Human Genetics, 2011, 89, 713-730.	2.6	178
413	HNF1AG319S variant, active cigarette smoking and incident type 2 diabetes in Aboriginal Canadians: a population-based epidemiological study. BMC Medical Genetics, 2011, 12, 1.	2.1	39
414	Evaluation of adipose tissue volume quantification with IDEAL fatâ€“water separation. Journal of Magnetic Resonance Imaging, 2011, 34, 474-479.	1.9	26

#	Article	IF	Citations
415	Sortilin: An unusual suspect in cholesterol metabolism. BioEssays, 2011, 33, 430-437.	1.2	36
416	Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor. Expert Opinion on Pharmacotherapy, 2011, 12, 675-678.	0.9	2
417	The transcription factor cyclic AMPâ€“responsive elementâ€“binding protein H regulates triglyceride metabolism. Nature Medicine, 2011, 17, 812-815.	15.2	174
418	An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1916-1926.	1.1	84
419	Genetic risk factors for stroke in the genome-wide association era. Expert Opinion on Medical Diagnostics, 2011, 5, 75-84.	1.6	0
420	Genetic determinants of plasma triglycerides. Journal of Lipid Research, 2011, 52, 189-206.	2.0	223
421	Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration. Blood, 2010, 116, 2160-2163.	0.6	9
422	Temtamy Preaxial Brachydactyly Syndrome Is Caused by Loss-of-Function Mutations in Chondroitin Synthase 1, a Potential Target of BMP Signaling. American Journal of Human Genetics, 2010, 87, 757-767.	2.6	86
423	Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study. Cardiovascular Diabetology, 2010, 9, 39.	2.7	9
424	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	13.7	3,249
425	Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nature Genetics, 2010, 42, 684-687.	9.4	414
426	Kinase mutations in human disease: interpreting genotypeâ€“phenotype relationships. Nature Reviews Genetics, 2010, 11, 60-74.	7.7	330
427	Rare ATGL haplotypes are associated with increased plasma triglyceride concentrations in the Greenland Inuit. International Journal of Circumpolar Health, 2010, 69, 3-12.	0.5	5
428	Association of Apolipoprotein B with Incident Type 2 Diabetes in an Aboriginal Canadian Population1. Clinical Chemistry, 2010, 56, 666-670.	1.5	56
429	Extremes of Unexplained Variation as a Phenotype. Circulation: Cardiovascular Genetics, 2010, 3, 215-221.	5.1	48
430	APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians. Journal of Lipid Research, 2010, 51, 843-848.	2.0	13
431	Genome-Wide Association Studies of Plasma Lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2084-2086.	1.1	6
432	Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 2010, 51, 1201-1207.	2.0	48

#	Article	IF	Citations
433	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. Journal of Clinical Investigation, 2010, 120, 2889-2899.	3.9	71
434	Advances in Genomic Analysis of Stroke. Stroke, 2010, 41, 825-832.	1.0	70
435	Increased Blood Pressure and Hyperdynamic Cardiovascular Responses in Carriers of a Common Hyperfunctional Variant of Adenylyl Cyclase 6. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 451-457.	1.3	17
436	Comprehensive Analysis of Genomic Variation in the LPA Locus and Its Relationship to Plasma Lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circulation: Cardiovascular Genetics, 2010, 3, 39-46.	5.1	120
437	Phenomics: Expanding the Role of Clinical Evaluation in Genomic Studies. Journal of Investigative Medicine, 2010, 58, 700-706.	0.7	42
438	Translating genomic analyses into improved management of coronary artery disease. Future Cardiology, 2010, 6, 507-521.	0.5	6
439	Advances in Stroke 2009. Stroke, 2010, 41, e63-6.	1.0	8
440	A Translational View of the Genetics of Lipodystrophy and Ectopic Fat Deposition. Progress in Molecular Biology and Translational Science, 2010, 94, 159-196.	0.9	14
441	Effects of Intensive Medical Therapy on Microemboli and Cardiovascular Risk in Asymptomatic Carotid Stenosis. Archives of Neurology, 2010, 67, 180.	4.9	318
442	Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2010, 11, 2569-2572.	0.9	18
443	Complete Apo AI Deficiency in an Iraqi Mandaean Family: Case studies and review of the literature. Journal of Clinical Lipidology, 2010, 4, 420-426.	0.6	13
444	Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutation. Journal of Clinical Lipidology, 2010, 4, 310-313.	0.6	6
445	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	0.8	191
446	Hepatic lipase deficiency in a Middle-Eastern-Arabic male. BMJ Case Reports, 2010, 2010, bcr1220092589-bcr1220092589.	0.2	6
447	Phenomics: expanding the role of clinical evaluation in genomic studies. Journal of Investigative Medicine, 2010, 58, 700-6.	0.7	21
448	Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. Journal of Lipid Research, 2009, 50, 1223-1228.	2.0	56
449	Comparison of Gadofluorine-M and Gd-DTPA for Noninvasive Staging of Atherosclerotic Plaque Stability Using MRI. Circulation: Cardiovascular Imaging, 2009, 2, 226-234.	1.3	28
450	Enzyme-Sensitive Magnetic Resonance Imaging Targeting Myeloperoxidase Identifies Active Inflammation in Experimental Rabbit Atherosclerotic Plaques. Circulation, 2009, 120, 592-599.	1.6	151

#	Article	IF	Citations
451	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. Journal of Lipid Research, 2009, 50, 1487-1496.	2.0	54
452	A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Human Molecular Genetics, 2009, 18, 4189-4194.	1.4	88
453	Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. Brain, 2009, 132, 1346-1354.	3.7	16
454	Update on the Genetics of Stroke and Cerebrovascular Disease 2008. Stroke, 2009, 40, e289-91.	1.0	2
455	Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. Journal of Lipid Research, 2009, 50, 768-772.	2.0	42
456	Multi-Ethnic Genetic Association Study of Carotid Intima-Media Thickness Using a Targeted Cardiovascular SNP Microarray. Stroke, 2009, 40, 3173-3179.	1.0	32
457	Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. Journal of Lipid Research, 2009, 50, 1216-1222.	2.0	24
458	Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design?. PLoS Genetics, 2009, 5, e1000694.	1.5	62
459	Narrative Review: Statin-Related Myopathy. Annals of Internal Medicine, 2009, 150, 858.	2.0	369
460	Hypertriglyceridemia: phenomics and genomics. Molecular and Cellular Biochemistry, 2009, 326, 35-43.	1.4	49
461	Plasma lipoproteins: genetic influences and clinical implications. Nature Reviews Genetics, 2009, 10, 109-121.	7.7	367
462	Lessons from Genetic Studies in Native Canadian Populations. Nutrition Reviews, 2009, 57, 43-50.	2.6	5
463	A Multiplex Human Syndrome Implicates a Key Role for Intestinal Cell Kinase in Development of Central Nervous, Skeletal, and Endocrine Systems. American Journal of Human Genetics, 2009, 84, 134-147.	2.6	58
464	A Multiplex Human Syndrome Implicates a Key Role for Intestinal Cell Kinase in Development of Central Nervous, Skeletal, and Endocrine Systems. American Journal of Human Genetics, 2009, 84, 822.	2.6	3
465	Cystathionine Î³-lyase: Clinical, metabolic, genetic, and structural studies. Molecular Genetics and Metabolism, 2009, 97, 250-259.	0.5	57
466	Predicting abdominal adipose tissue among women with familial partial lipodystrophy. Metabolism: Clinical and Experimental, 2009, 58, 828-834.	1.5	15
467	Predictive genetic testing for coronary artery disease. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 343-360.	2.7	14
468	Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. Genome Medicine, 2009, 1, 28.	3.6	54

#	Article	IF	Citations
469	Triple X syndrome in a patient with partial lipodystrophy discovered using a high-density oligonucleotide microarray: a case report. Journal of Medical Case Reports, 2009, 3, 8867.	0.4	4
470	Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptorâ€“Null Mice With Diet-Induced Insulin Resistance. Diabetes, 2009, 58, 2198-2210.	0.3	254
471	NovelLPLmutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Canadian Journal of Physiology and Pharmacology, 2009, 87, 151-160.	0.7	76
472	Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. Atherosclerosis, 2009, 203, 192-200.	0.4	37
473	Letter to the editor. Canadian Journal of Cardiology, 2009, 25, 453.	0.8	5
474	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
475	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult â€“ 2009 recommendations. Canadian Journal of Cardiology, 2009, 25, 567-579.	0.8	653
476	Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. Cmaj, 2009, 180, 617-624.	0.9	55
477	The end of the road for CETP inhibitors after torcetrapib?. Current Opinion in Cardiology, 2009, 24, 364-371.	0.8	38
478	Lipid-altering gene variants and cardiovascular risk in the older population. Clinical Lipidology, 2009, 4, 721-724.	0.4	0
479	Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. Journal of Clinical Investigation, 2009, 119, 1042-50.	3.9	162
480	Hoofbeats, zebras, and insights into insulin resistance. Journal of Clinical Investigation, 2009, 119, 249-51.	3.9	2
481	Genetics of Metabolic Syndrome and Genetic Lipodystrophies. , 2009, , 63-81.		0
482	Genetics of metabolic syndrome: Is there a role for phenomics?. Current Atherosclerosis Reports, 2008, 10, 201-208.	2.0	33
483	Genetics of metabolic syndrome. Current Diabetes Reports, 2008, 8, 141-148.	1.7	57
484	Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovascular Diabetology, 2008, 7, 5.	2.7	87
485	The failure of torcetrapib: what have we learned?. British Journal of Pharmacology, 2008, 154, 1379-1381.	2.7	42
486	Is raising HDL a futile strategy for atheroprotection?. Nature Reviews Drug Discovery, 2008, 7, 143-155.	21.5	129

#	Article	IF	Citations
487	Variation in Niemannâ€“Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clinical Endocrinology, 2008, 69, 45-51.	1.2	16
488	Abetalipoproteinemia: two case reports and literature review. Orphanet Journal of Rare Diseases, 2008, 3, 19.	1.2	168
489	Familial hypobetalipoproteinemia due to a novel early stop mutation. Journal of Clinical Lipidology, 2008, 2, 384-390.	0.6	4
490	Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids in Health and Disease, 2008, 7, 3.	1.2	124
491	Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum. Molecular Genetics and Metabolism, 2008, 93, 282-294.	0.5	66
492	Emerging antidyslipidemic drugs. Expert Opinion on Emerging Drugs, 2008, 13, 363-381.	1.0	14
493	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.	0.8	78
494	Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: Resolved and unresolved issues. Canadian Journal of Cardiology, 2008, 24, 293-300.	0.8	15
495	Genetic testing for atherosclerosis risk: Inevitability or pipe dream?. Canadian Journal of Cardiology, 2008, 24, 851-854.	0.8	11
496	Lipoprotein(a) Is Associated Differentially With Carotid Stenosis, Occlusion, and Total Plaque Area. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1851-1856.	1.1	66
497	Association of the FABP2 T54 Variant with Plasma Triglycerides and Insulin Resistance in a Multiethnic Population. Clinical Chemistry, 2008, 54, 1742-1744.	1.5	5
498	Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. Journal of Lipid Research, 2008, 49, 349-357.	2.0	57
499	APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 730-737.	3.3	54
500	An Unusual Case of Severe Hypertriglyceridemia and Splenomegaly. Clinical Chemistry, 2008, 54, 606-610.	1.5	9
501	Adipokines and Incident Type 2 Diabetes in an Aboriginal Canadian Population. Diabetes Care, 2008, 31, 1410-1415.	4.3	72
502	Predictors of Mammographic Density: Insights Gained from a Novel Regression Analysis of a Twin Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3474-3481.	1.1	52
503	Update on the Genetics of Stroke and Cerebrovascular Disease 2007. Stroke, 2008, 39, 252-254.	1.0	6
504	Microsomal triglyceride transfer protein inhibitionâ€“friend or foe?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 506-508.	3.3	15

#	Article	IF	Citations
505	Uncloaking the Genetic Determinants of Metabolic Syndrome. Journal of Nutrigenetics and Nutrigenomics, 2008, 1, 118-125.	1.8	12
506	Polygenic determinants of severe hypertriglyceridemia. Human Molecular Genetics, 2008, 17, 2894-2899.	1.4	118
507	Constructing Treatment Portfolios Using Affinity Propagation. Lecture Notes in Computer Science, 2008, , 360-371.	1.0	25
508	Prevalence of Reproductive Abnormalities Among Women with Familial Partial Lipodystrophy. Endocrine Practice, 2008, 14, 1126-1132.	1.1	21
509	Missense Mutations in APOB within the Î²Î±1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2007, 282, 24270-24283.	1.6	66
510	Selective Up-regulation of LXR-regulated Genes ABCA1, ABCG1, and APOE in Macrophages through Increased Endogenous Synthesis of 24(S),25-Epoxycholesterol. Journal of Biological Chemistry, 2007, 282, 5207-5216.	1.6	94
511	Copy Number Variation in the Human Genome and Its Implications for Cardiovascular Disease. Circulation, 2007, 115, 3130-3138.	1.6	66
512	Genetic determinants of plasma lipoproteins. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 600-609.	3.3	15
513	Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency. Nephrology Dialysis Transplantation, 2007, 22, 2084-2088.	0.4	18
514	Copy-number variations add a new layer of complexity in the human genome. Cmaj, 2007, 176, 441-442.	0.9	6
515	Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation. Cmaj, 2007, 177, 743-745.	0.9	10
516	Treating hypertriglyceridemia. Cmaj, 2007, 177, 604.2-605.	0.9	0
517	Familial Partial Lipodystrophy Phenotype Resulting from a Single-Base Mutation in Deoxyribonucleic Acid-Binding Domain of Peroxisome Proliferator-Activated Receptor-Î³. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1606-1612.	1.8	53
518	Phenomics, Lamin A/C, and Metabolic Disease. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4566-4568.	1.8	6
519	Update on the Genetics of Stroke and Cerebrovascular Disease 2006. Stroke, 2007, 38, 216-218.	1.0	15
520	Resequencing Genomic DNA of Patients With Severe Hypertriglyceridemia (MIM 144650). Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2450-2455.	1.1	94
521	Increased Enzyme Activity and Î²-Adrenergicâ€“Mediated Vasodilation in Subjects Expressing a Single-Nucleotide Variant of Human Adenylyl Cyclase 6. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2657-2663.	1.1	11
522	Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism. Journal of Lipid Research, 2007, 48, 1433-1444.	2.0	122

#	Article	IF	Citations
523	Sanfilippo Syndrome Type D. Archives of Neurology, 2007, 64, 1629.	4.9	29
524	Hypertriglyceridemia: its etiology, effects and treatment. Cmaj, 2007, 176, 1113-1120.	0.9	443
525	Apolipoprotein A-V Genetic Variation and Plasma Lipoprotein Response to Fibrates. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1224-1227.	1.1	10
526	Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders. International Journal of Circumpolar Health, 2007, 66, 390-400.	0.5	17
527	Genomic copy number variation and its potential role in lipoprotein and metabolic phenotypes. Current Opinion in Lipidology, 2007, 18, 174-180.	1.2	20
528	Copy-Number Variations and Human Disease. American Journal of Human Genetics, 2007, 81, 414-415.	2.6	10
529	HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infectious Diseases, The, 2007, 7, 787-796.	4.6	125
530	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2007, 23, 539-550.	0.8	87
531	Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids in Health and Disease, 2007, 6, 23.	1.2	74
532	Genetic determinants of statin intolerance. Lipids in Health and Disease, 2007, 6, 7.	1.2	134
533	Alstrom syndrome (OMIM 203800): a case report and literature review. Orphanet Journal of Rare Diseases, 2007, 2, 49.	1.2	58
534	Efficacy and Safety of Pioglitazone in Treatment of a Patient with an Atypical Partial Lipodystrophy Syndrome. Endocrine Practice, 2007, 13, 656-661.	1.1	19
535	MRI of earlyâ€•and lateâ€stage arterial remodeling in a lowâ€level cholesterolâ€fed rabbit model of atherosclerosis. Journal of Magnetic Resonance Imaging, 2007, 26, 1010-1019.	1.9	12
536	Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Medical Imaging, 2007, 7, 3.	1.4	24
537	Association between the -455T>C promoter polymorphism of the APOC3gene and the metabolic syndrome in a multi-ethnic sample. BMC Medical Genetics, 2007, 8, 80.	2.1	39
538	Response to Landires et al.. Clinical Genetics, 2007, 71, 594-596.	1.0	1
539	Inherited lipodystrophies and the metabolic syndrome. Clinical Endocrinology, 2007, 67, 070611020455003-???.	1.2	18
540	Phenomics and lamins: From disease to therapy. Experimental Cell Research, 2007, 313, 2134-2143.	1.2	21

#	Article	IF	Citations
541	Genetic Forms of the Cardiometabolic Syndrome: What Can They Tell the Clinician?. Journal of the Cardiometabolic Syndrome, 2007, 2, 45-48.	1.7	5
542	Peroxisome proliferator-activated receptor Î³ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Journal of Diabetes and Its Complications, 2007, 21, 166-171.	1.2	32
543	Decreased Abdominal Girth and Increased Blood Pressure Associated With a Single Nucleotide Variant of Human Adenylyl Cyclase 6. FASEB Journal, 2007, 21, A795.	0.2	0
544	Genetic susceptibility to heart disease in Canada: lessons from patients with familial hypercholesterolemia. Genome, 2006, 49, 1343-1350.	0.9	19
545	Sequencing of the Reannotated LMNB2 Gene Reveals Novel Mutations in Patients with Acquired Partial Lipodystrophy. American Journal of Human Genetics, 2006, 79, 383-389.	2.6	177
546	Metabolic syndrome in aboriginal Canadians: Prevalence and genetic associations. Atherosclerosis, 2006, 184, 121-129.	0.4	83
547	A novel nonsense apolipoprotein A-I mutation (apoA-IE136X) causes low HDL cholesterol in French Canadians. Atherosclerosis, 2006, 185, 127-136.	0.4	39
548	Genetic determinants of the metabolic syndrome. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 482-489.	3.3	138
549	Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. Cmaj, 2006, 174, 1124-1129.	0.9	94
550	NPC1L1: from drug target to physiological sterol transporter. Future Lipidology, 2006, 1, 247-249.	0.5	0
551	Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. BMC Medical Imaging, 2006, 6, 11.	1.4	30
552	Peroxisomal proliferator activated receptor-Î³ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Medical Genetics, 2006, 7, 3.	2.1	54
553	Relationship of the metabolic syndrome to carotid ultrasound traits. Cardiovascular Ultrasound, 2006, 4, 28.	0.5	35
554	A frameshift mutation in peroxisome-proliferator-activated receptor-Î³ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clinical Genetics, 2006, 70, 360-362.	1.0	26
555	Cockayne syndrome type A: novel mutations in eight typical patients. Journal of Human Genetics, 2006, 51, 701-705.	1.1	28
556	Ankyrin G overexpression in Hutchinson-Gilford progeria syndrome fibroblasts identified through biological filtering of expression profiles. Journal of Human Genetics, 2006, 51, 934-942.	1.1	13
557	Genetic determinants of carotid ultrasound traits. Current Atherosclerosis Reports, 2006, 8, 206-215.	2.0	50
558	ALMNASplicing Mutation in Two Sisters with Severe Dunnigan-Type Familial Partial Lipodystrophy Type 2. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2689-2695.	1.8	42

#	Article	IF	Citations
559	Validation of Automatically Classified Magnetic Resonance Images for Carotid Plaque Compositional Analysis. Stroke, 2006, 37, 93-97.	1.0	54
560	NPC1L1: Evolution From Pharmacological Target to Physiological Sterol Transporter. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2433-2438.	1.1	76
561	Longitudinal Differences in Familial Combined Hyperlipidemia Quantitative Trait Loci. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e120.	1.1	3
562	The Heritability of Mammographically Dense and Nondense Breast Tissue. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 612-617.	1.1	101
563	Gene Therapy With Lipoprotein Lipase Variant S447X. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e25; author reply e25-8.	1.1	4
564	The Impact of Blunted Î²-Adrenergic Responsiveness on Growth Regulatory Pathways in Hypertension. Molecular Pharmacology, 2006, 69, 317-327.	1.0	8
565	Quality assessment of microarray experiments. Clinical Biochemistry, 2005, 38, 639-642.	0.8	11
566	Identification of a dysfunctional missense single nucleotide variant of human adenylyl cyclase VI. Clinical Pharmacology and Therapeutics, 2005, 77, 271-278.	2.3	6
567	Synergism between mutant HNF1A and the metabolic syndrome in Oji-Cree Type 2 diabetes. Diabetic Medicine, 2005, 22, 1510-1515.	1.2	5
568	LMNA mutation position predicts organ system involvement in laminopathies. Clinical Genetics, 2005, 68, 31-34.	1.0	78
569	Lessons from human mutations in PPARÎ³. International Journal of Obesity, 2005, 29, S31-S35.	1.6	49
570	Novel mutation inDGUOK in hepatocerebral mitochondrial DNA depletion syndrome associated with cystathioninuria. American Journal of Medical Genetics, Part A, 2005, 135A, 289-291.	0.7	39
571	Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. Cardiovascular Diabetology, 2005, 4, 17.	2.7	28
572	A comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes. Cardiovascular Ultrasound, 2005, 3, 15.	0.5	42
573	Genetic and physiological insights into the metabolic syndrome. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 289, R663-R669.	0.9	46
574	Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. Journal of Lipid Research, 2005, 46, 366-372.	2.0	69
575	Complex Trait Locus Linkage Mapping in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1541-1544.	1.1	17
576	Retinoid X Receptor Heterodimers in the Metabolic Syndrome. New England Journal of Medicine, 2005, 353, 2088-2088.	13.9	10

#	Article	IF	Citations
577	Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia. Cmaj, 2005, 172, 495-497.	0.9	16
578	Regulation of Macrophage Cholesterol Efflux through Hydroxymethylglutaryl-CoA Reductase Inhibition. Journal of Biological Chemistry, 2005, 280, 22212-22221.	1.6	112
579	Complications of Type 2 Diabetes Among Aboriginal Canadians: Prevalence and associated risk factors. Diabetes Care, 2005, 28, 2054-2057.	4.3	69
580	Pituitary Growth Hormone and Growth Hormone-Releasing Hormone Receptor Genes and Associations with Mammographic Measures and Serum Growth Hormone. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2648-2654.	1.1	26
581	Disparate Associations of a Functional Promoter Polymorphism in PCK1 With Carotid Wall Ultrasound Traits. Stroke, 2005, 36, 2566-2570.	1.0	24
582	Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis, 2005, 178, 319-325.	0.4	91
583	Erratum to â€œDifferences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensionsâ€•[Atherosclerosis 178(2) (2005) 319â€“325]. Atherosclerosis, 2005, 182, 379-380.	0.4	1
584	Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids in Health and Disease, 2005, 4, 26.	1.2	52
585	NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids in Health and Disease, 2005, 4, 16.	1.2	111
586	Carotid Ultrasound in One, Two and Three Dimensions. Vascular Disease Prevention, 2005, 2, 87-91.	0.2	5
587	ABC Transporters and Sterol Absorption. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 31-37.	2.0	8
588	Postprandial lipemia in subjects with the threonine 54 variant of the fatty acid-binding protein 2 gene is dependent on the type of fat ingested. American Journal of Clinical Nutrition, 2004, 79, 1110-1117.	2.2	60
589	Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor Î³ Associated With Carotid Atherosclerosis. Stroke, 2004, 35, 2036-2040.	1.0	93
590	Non-Invasive Assessment of Atherosclerosis Risk. Current Drug Targets Cardiovascular & Haematological Disorders, 2004, 4, 125-128.	2.0	31
591	3D Ultrasound Imaging of the Carotid Arteries. Current Drug Targets Cardiovascular & Haematological Disorders, 2004, 4, 161-175.	2.0	39
592	Promoter Polymorphism inPCK1(Phosphoenolpyruvate Carboxykinase Gene) Associated with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 898-903.	1.8	48
593	A Single-Base Mutation in the Peroxisome Proliferator-Activated Receptor Î³4 Promoter Associated with Alteredin VitroExpression and Partial Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5655-5660.	1.8	69
594	The Metabolic Syndrome in Inuit. Diabetes Care, 2004, 27, 1517-1518.	4.3	6

#	Article	IF	Citations
595	Phenotypic heterogeneity of sitosterolemia. Journal of Lipid Research, 2004, 45, 2361-2367.	2.0	76
596	Laminopathies and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1591-1595.	1.1	50
597	Human Smooth Muscle Cell Subpopulations Differentially Accumulate Cholesteryl Ester When Exposed to Native and Oxidized Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1290-1296.	1.1	46
598	Noninvasive Phenotypes of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, e188; author reply e188-9.	1.1	39
599	Noninvasive Phenotypes of Atherosclerosis. Stroke, 2004, 35, 649-653.	1.0	140
600	Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. Clinical Genetics, 2004, 65, 483-486.	1.0	50
601	Hutchinson-Gilford progeria syndrome. Clinical Genetics, 2004, 66, 375-381.	1.0	142
602	Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clinical Genetics, 2004, 67, 175-177.	1.0	64
603	Phenomics, Lipodystrophy, and the Metabolic Syndrome. Trends in Cardiovascular Medicine, 2004, 14, 133-137.	2.3	33
604	CKN1 (MIM 216400): mutations in Cockayne syndrome type A and a new common polymorphism. Journal of Human Genetics, 2004, 49, 61-63.	1.1	24
605	Optimizing RNA extraction yield from whole blood for microarray gene expression analysis. Clinical Biochemistry, 2004, 37, 741-744.	0.8	30
606	Venn analysis as part of a bioinformatic approach to prioritize expressed sequence tags from cardiac libraries. Clinical Biochemistry, 2004, 37, 953-960.	0.8	4
607	Treatment of partial lipodystrophy: can the zebra teach us about the horse?. Drug Discovery Today Disease Mechanisms, 2004, 1, 195-203.	0.8	2
608	Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. Thrombosis Research, 2004, 114, 137-141.	0.8	12
609	Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis, 2004, 176, 361-370.	0.4	56
610	Is regression of coronary atherosclerosis possible by infusing recombinant apolipoprotein A-I?. Cmaj, 2004, 170, 954-954.	0.9	0
611	Unbuckling lipodystrophy from insulin resistance and hypertension. Journal of Clinical Investigation, 2004, 114, 163-165.	3.9	17
612	Unbuckling lipodystrophy from insulin resistance and hypertension. Journal of Clinical Investigation, 2004, 114, 163-165.	3.9	10

#	Article	IF	Citations
613	A glimpse at HDL-based therapy for atherosclerosis. Clinical Biochemist Reviews, 2004, 25, 3-5.	3.3	27
614	Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY). Clinical and Investigative Medicine, 2004, 27, 135-41.	0.3	7
615	LMNA is mutated in Hutchinson-Gilford progeria (MIMÂ176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIMÂ264090). Journal of Human Genetics, 2003, 48, 271-274.	1.1	205
616	DNA polymorphisms of lipase related genes. Journal of Human Genetics, 2003, 48, 443-446.	1.1	11
617	DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. Journal of Human Genetics, 2003, 48, 0020-0022.	1.1	27
618	Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Human Genetics, 2003, 112, 404-408.	1.8	74
619	Genes, environment and Oji-Cree type 2 diabetes. Clinical Biochemistry, 2003, 36, 163-170.	0.8	52
620	Apoa1 related amyloidosis: a case report and literature review. Clinical Biochemistry, 2003, 36, 641-645.	0.8	53
621	Lamin mutations come of age. Nature Medicine, 2003, 9, 644-645.	15.2	14
622	Low incidence of cardiovascular disease among the Inuitâ€"what is the evidence?. Atherosclerosis, 2003, 166, 351-357.	0.4	90
623	Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans. Human Molecular Genetics, 2003, 12, 1131-1143.	1.4	27
624	Drawing the line in progeria syndromes. Lancet, The, 2003, 362, 416-417.	6.3	24
625	Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase. Genomics, 2003, 81, 1-5.	1.3	38
626	Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends in Endocrinology and Metabolism, 2003, 14, 371-377.	3.1	79
627	Biophysical characteristics of a new mutation on the KCNQ1 potassium channel (L251P) causing long QT syndrome. Canadian Journal of Physiology and Pharmacology, 2003, 81, 129-134.	0.7	10
628	Enhanced Synthesis of the Oxysterol 24(S),25-Epoxycholesterol in Macrophages by Inhibitors of 2,3-Oxidosqualene:Lanosterol Cyclase. Circulation Research, 2003, 93, 717-725.	2.0	90
629	Blood pressure among the Inuit (Eskimo) populations in the Arctic. Scandinavian Journal of Public Health, 2003, 31, 92-99.	1.2	38
630	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. Journal of Lipid Research, 2003, 44, 1508-1514.	2.0	26

#	Article	IF	Citations
631	Free Fatty Acid-Mediated Impairment of Glucose-Stimulated Insulin Secretion in Nondiabetic Oji-Cree Individuals From the Sandy Lake Community of Ontario, Canada: A Population at Very High Risk for Developing Type 2 Diabetes. Diabetes, 2003, 52, 1485-1495.	0.3	32
632	A Novel Nontruncating APOB Gene Mutation, R463W, Causes Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2003, 278, 13442-13452.	1.6	82
633	Sex, Diabetes, and Stroke After Carotid Endarterectomy. Diabetes Care, 2003, 26, 1641-1641.	4.3	36
634	Aortic Xanthomatosis With Coronary Ostial Occlusion in a Child Homozygous for a Nonsense Mutation in ABCG8. Circulation, 2003, 107, 791-791.	1.6	49
635	Maturity-Onset Diabetes of the Young (MODY) Mutation in Type 2 Diabetes and Latent Autoimmune Diabetes of the Adult. Diabetes Care, 2003, 26, 3358-3359.	4.3	5
636	Genomic Organization and Evolution of the CX3CR1/CCR8 Chemokine Receptor Locus. Journal of Biological Chemistry, 2003, 278, 11985-11994.	1.6	22
637	Assembly and Secretion of Very Low Density Lipoproteins Containing Apolipoprotein B48 in Transfected McA-RH7777 Cells. Journal of Biological Chemistry, 2003, 278, 14153-14161.	1.6	17
638	Elevated Serum C-Reactive Protein and Free Fatty Acids Among Nondiabetic Carriers of Missense Mutations in the Gene Encoding Lamin A/C (LMNA) With Partial Lipodystrophy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 111-116.	1.1	64
639	Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction1. Transplantation, 2003, 75, 209-216.	0.5	10
640	Survival in Academy Awardâ€“Winning Actors and Actresses. Annals of Internal Medicine, 2003, 138, 77.	2.0	4
641	Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thrombosis and Haemostasis, 2003, 90, 1187-1191.	1.8	18
642	Lipoprotein Lipase (LPL) Gene Variation and Progression of Carotid Artery Plaque. Stroke, 2003, 34, 1176-1180.	1.0	41
643	The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. Journal of Clinical Investigation, 2003, 111, 1118-1120.	3.9	31
644	Association of Parity With Risk of Type 2 Diabetes and Related Metabolic Disorders. Diabetes Care, 2002, 25, 690-695.	4.3	35
645	HNF-1Â G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4614-4619.	3.3	110
646	Functional Linkage between the Endoplasmic Reticulum Protein Hsp47 and Procollagen Expression in Human Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2002, 277, 38571-38578.	1.6	54
647	Cross-Sectional and Prospective Associations between Abdominal Adiposity and Proinsulin Concentration. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 77-83.	1.8	26
648	A Single Nucleotide Polymorphism in Protein Tyrosine Phosphatase PTP-1B Is Associated with Protection from Diabetes or Impaired Glucose Tolerance in Oji-Cree. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 724-727.	1.8	70

#	Article	IF	Citations
649	PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy. Diabetes, 2002, 51, 3586-3590.	0.3	246
650	Rapid Development of Massive Tendon Xanthomas following Highly Active Antiretroviral Therapy. Annals of Internal Medicine, 2002, 137, 624.	2.0	14
651	Environmental modulation of atherosclerosis end points in familial hypercholesterolemia. Atherosclerosis Supplements, 2002, 2, 5-7.	1.2	21
652	Beta blockers normalize QT hysteresis in long QT syndrome. American Heart Journal, 2002, 143, 528-534.	1.2	46
653	The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. Diabetes Research and Clinical Practice, 2002, 55, 165-173.	1.1	60
654	A BRCA1 mutation in Native North American families. Human Mutation, 2002, 19, 460-460.	1.1	16
655	GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY). Human Mutation, 2002, 20, 478-479.	1.1	19
656	Identification of single-nucleotide polymorphisms in the human LPIN1 gene. Journal of Human Genetics, 2002, 47, 370-372.	1.1	21
657	Functional promoter polymorphism in SREBP cleavage-activating protein (SCAP). Journal of Human Genetics, 2002, 47, 492-496.	1.1	5
658	Polymorphisms in the gene encoding phosphatidylserine-specific phospholipase A1 (PSPLA1). Journal of Human Genetics, 2002, 47, 0611-0613.	1.1	2
659	DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. Journal of Human Genetics, 2002, 47, 0620-0622.	1.1	87
660	The molecular basis of genetic lipodystrophies. Clinical Biochemistry, 2002, 35, 171-177.	0.8	22
661	Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. Clinical Biochemistry, 2002, 35, 125-130.	0.8	33
662	Gene-drug interaction: additive influence of mutant APOA1 and testosterone on plasma HDL-cholesterol. Clinical Biochemistry, 2002, 35, 341-346.	0.8	0
663	SNP Judgments and Freedom of Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1058-1061.	1.1	103
664	Identification of polymorphisms in the human SHP1 gene. Journal of Human Genetics, 2002, 47, 445-447.	1.1	17
665	Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis, 2001, 154, 579-587.	0.4	30
666	Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis, 2001, 159, 231-236.	0.4	48

#	Article	IF	Citations
667	Monogenic Dyslipidemias: Window on Determinants of Plasma Lipoprotein Metabolism. American Journal of Human Genetics, 2001, 69, 1161-1177.	2.6	73
668	Molecular basis of partial lipodystrophy and prospects for therapy. Trends in Molecular Medicine, 2001, 7, 121-126.	3.5	36
669	Serum C-Reactive Protein in Canadian Inuit and Its Association with Genetic Variation on Chromosome 1q21. Clinical Chemistry, 2001, 47, 1707-1709.	1.5	9
670	Apolipoprotein E Polymorphism and Response to Electroconvulsive Therapy. Journal of ECT, 2001, 17, 11-14.	0.3	13
671	Genes and environment in type 2 diabetes and atherosclerosis in aboriginal canadians. Current Atherosclerosis Reports, 2001, 3, 216-221.	2.0	19
672	Single nucleotide polymorphisms of the resistin (RSTN) gene. Journal of Human Genetics, 2001, 46, 553-555.	1.1	28
673	Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. Human Mutation, 2001, 18, 359-359.	1.1	32
674	Lecithin:cholesterol acyl transferase G30S: association with atherosclerosis, hypoalphalipoproteinemia and reduced in vivo enzyme activity. Clinical Biochemistry, 2001, 34, 381-386.	0.8	9
675	Transforming Growth Factor-Î²1 Inhibits Macrophage Cholesteryl Ester Accumulation Induced by Native and Oxidized VLDL Remnants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 2011-2018.	1.1	78
676	Premature Atherosclerosis Associated With Monogenic Insulin Resistance. Circulation, 2001, 103, 2225-2229.	1.6	136
677	Common Genomic Variation inLMNAModulates Indexes of Obesity in Inuit1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2747-2751.	1.8	45
678	Allele Frequencies for Candidate Genes in Atherosclerosis and Diabetes among Trinidadian Neonates. Human Biology, 2001, 73, 525-531.	0.4	4
679	Genes, Environment and Diabetes in Canadian Aboriginal Communities. Advances in Experimental Medicine and Biology, 2001, 498, 11-20.	0.8	12
680	RECIPIENT ANGIOTENSINOGEN GENE VARIANTS BUT NOT THE ACE INSERTION/DELETION POLYMORPHISM PREDICT RATE OF DECLINE IN RENAL ALLOGRAFT FUNCTION.. Transplantation, 2000, 69, S400-S401.	0.5	0
681	Association between PON1 L/M55 Polymorphism and Plasma Lipoproteins in Two Canadian Aboriginal Populations. Clinical Chemistry and Laboratory Medicine, 2000, 38, 413-20.	1.4	26
682	Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia. , 2000, 15, 294-295.		57
683	The envelope, please: Nuclear lamins and disease. Nature Medicine, 2000, 6, 136-137.	15.2	23
684	Insulin resistance in human partial lipodystrophy. Current Atherosclerosis Reports, 2000, 2, 397-404.	2.0	12

#	Article	IF	Citations
685	Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. Journal of Human Genetics, 2000, 45, 92-93.	1.1	19
686	Human cathepsin S gene (CTSS) promoter â^'25G/A polymorphism. Journal of Human Genetics, 2000, 45, 94-95.	1.1	6
687	Human hepatocyte nuclear factor-1Î² (HNF1B) 1968A/G polymorphism. Journal of Human Genetics, 2000, 45, 98-99.	1.1	1
688	Human C-reactive protein (CRP) 1059G/C polymorphism. Journal of Human Genetics, 2000, 45, 100-101.	1.1	68
689	Genetic variation inLMNAmodulates plasma leptin and indices of obesity in aboriginal Canadians. Physiological Genomics, 2000, 3, 39-44.	1.0	59
690	Peroxisome Proliferator-Activated Receptor-Î³2 P12A and Type 2 Diabetes in Canadian Oji-Cree*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2014-2019.	1.8	65
691	Heterogeneity of Nuclear Lamin A Mutations in Dunnigan-Type Familial Partial Lipodystrophy*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3431-3435.	1.8	57
692	LMNA R482Q Mutation in Partial Lipodystrophy Associated with Reduced Plasma Leptin Concentration*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3089-3093.	1.8	44
693	Variation of Candidate Genes in Triglyceride Metabolism. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 309-315.	3.1	16
694	Common and Rare ABCA1 Variants Affecting Plasma HDL Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1983-1989.	1.1	117
695	The Private Hepatocyte Nuclear Factor-1Î± G319S Variant Is Associated With Plasma Lipoprotein Variation in Canadian Oji-Cree. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 217-222.	1.1	22
696	Familial Partial Lipodystrophy: A Monogenic Form of the Insulin Resistance Syndrome. Molecular Genetics and Metabolism, 2000, 71, 539-544.	0.5	58
697	A novel mutation in KVLQT1 , L122P, found in a family with autosomal dominant long QT syndrome. American Heart Journal, 2000, 140, 146-149.	1.2	7
698	Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: A prospective study. American Heart Journal, 2000, 140, 272-278.	1.2	41
699	G-protein polymorphisms and maternal/neonatal metabolism: still a weight for the answer. Lancet, The, 2000, 355, 1201-1202.	6.3	10
700	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet, The, 2000, 356, 279-284.	6.3	866
701	NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree. Pharmacogenetics and Genomics, 2000, 10, 233-238.	5.7	15
702	Uncovering Rare Mutations: An Unforeseen Complication of Routine Genotyping of APOE. Clinical Chemistry, 1999, 45, 1579-1581.	1.5	5

#	Article	IF	Citations
703	Mannose-binding Lectin Gene Variation and Cardiovascular Disease in Canadian Inuit. Clinical Chemistry, 1999, 45, 1283-1285.	1.5	23
704	The Hepatic Nuclear Factor-1Î± G319S Variant Is Associated with Early-Onset Type 2 Diabetes in Canadian Oji-Cree1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1077-1082.	1.8	123
705	Modification of Type III VLDL, Their Remnants, and VLDL From ApoE-Knockout Mice by p -Hydroxyphenylacetaldehyde, a Product of Myeloperoxidase Activity, Causes Marked Cholesteryl Ester Accumulation in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1238-1249.	1.1	28
706	Genetic prediction of coronary heart disease: Lessons from Canada. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 153-167.	0.6	1
707	Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nature Genetics, 1999, 22, 325-326.	9.4	166
708	Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. Clinical Biochemistry, 1999, 32, 143-148.	0.8	13
709	Association between AGT T235 variant and microalbuminuria in Canadian Oji-cree with type 2 diabetes mellitus. Clinical Biochemistry, 1999, 32, 201-205.	0.8	7
710	Lipoprotein-genotype associations in Trinidadian neonates. Clinical Biochemistry, 1999, 32, 429-437.	0.8	11
711	The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree. Journal of Human Genetics, 1999, 44, 225-229.	1.1	11
712	Lipoprotein(a) and coronary heart disease risk. Current Cardiology Reports, 1999, 1, 105-111.	1.3	31
713	Paraoxonase Genes and Disease. Annals of Medicine, 1999, 31, 217-224.	1.5	90
714	Genetic prediction of atherosclerosis: lessons from studies in native Canadian populations. Clinica Chimica Acta, 1999, 286, 47-61.	0.5	22
715	An approach to ascertain probands with a non-traditional risk factor for carotid atherosclerosis. Atherosclerosis, 1999, 144, 429-434.	0.4	78
716	Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis, 1999, 146, 153-160.	0.4	61
717	HFE S65C Variant Is Not Associated with Increased Transferrin Saturation in Voluntary Blood Donors. Blood Cells, Molecules, and Diseases, 1999, 25, 354-357.	0.6	35
718	Plasma Homocyst(e)ine Concentration, But Not MTHFR Genotype, Is Associated With Variation in Carotid Plaque Area. Stroke, 1999, 30, 969-973.	1.0	118
719	Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics and Genomics, 1999, 9, 351-356.	5.7	34
720	Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-Î³. Journal of Lipid Research, 1999, 40, 1017-1028.	2.0	20

#	Article	IF	Citations
721	A review of intestinal fatty acid binding protein gene variation and the plasma lipoprotein response to dietary components. Clinical Biochemistry, 1998, 31, 609-612.	0.8	41
722	Genetics in childhood atherosclerosis. Progress in Pediatric Cardiology, 1998, 9, 213-224.	0.2	0
723	Hepatic Lipase Deficiency. Critical Reviews in Clinical Laboratory Sciences, 1998, 35, 547-572.	2.7	82
724	Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis, 1998, 139, 131-136.	0.4	62
725	Variation in the AU(AT)-Rich Element within the 3â€²-Untranslated Region ofPPP1R3Is Associated with Variation in Plasma Glucose in Aboriginal Canadians¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3980-3983.	1.8	27
726	Elevated LDL Triglyceride Concentrations in Subjects Heterozygous for the Hepatic Lipase S267F Variant. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1212-1216.	1.1	11
727	G Protein Î²3 Subunit Gene Variant and Blood Pressure Variation in Canadian Oji-Cree. Hypertension, 1998, 32, 688-692.	1.3	66
728	Hemochromatosis and Diabetes Mellitus. Annals of Internal Medicine, 1998, 129, 587.	2.0	11
729	Genetic variation in paraoxonaseâ€2 is associated with variation in plasma lipoproteins in Canadian Ojiâ€Cree. Clinical Genetics, 1998, 54, 394-399.	1.0	23
730	Paraoxonase-2 Gene (PON2) G148 Variant Associated with Elevated Fasting Plasma Glucose in Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3373-3377.	1.8	75
731	1.P.247 Apolipoprotein ER112; R251G: A carboxy-terminal variant associated with hyperlipidemia and vascular disease. Atherosclerosis, 1997, 134, 68-69.	0.4	0
732	1.P.292 Genetic variation in factor VII associated with variation in plasma lipoprotein(a) concentration. Atherosclerosis, 1997, 134, 78.	0.4	0
733	V677 mutation of methylenetetrahydrofolate reductase and cardiovascular disease in Canadian Inuit. Lancet, The, 1997, 349, 1221-1222.	6.3	56
734	Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet, The, 1997, 350, 785.	6.3	16
735	A Common mtDNA Polymorphism Associated with Variation in Plasma Triglyceride Concentration. American Journal of Human Genetics, 1997, 60, 1552-1555.	2.6	21
736	Apolipoprotein E R112; R251G: a carboxy-terminal variant found in patients with hyperlipidemia and coronary heart disease. Mutation Research - Mutation Research Genomics, 1997, 382, 57-65.	1.2	1
737	Evidence for gene-diet interaction in the response of blood pressure to dietary fibre. Nutrition Research, 1997, 17, 1229-1238.	1.3	9
738	Uptake of Type III Hypertriglyceridemic VLDL by Macrophages Is Enhanced by Oxidation, Especially After Remnant Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1707-1715.	1.1	51

#	Article	IF	Citations
739	Common Genomic Variation in the APOC3 Promoter Associated With Variation in Plasma Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2753-2758.	1.1	71
740	Small genetic effects in complex diseases: A review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clinical Biochemistry, 1997, 30, 183-188.	0.8	12
741	Is it time to measure Lp(a) as part of coronary heart disease risk assessment?. Clinical Biochemistry, 1997, 30, 443-445.	0.8	2
742	Common Genomic Variants Associated With Variation in Plasma Lipoproteins in Young Aboriginal Canadians. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1060-1066.	1.1	58
743	Genetic Variation in Factor VII Associated with Variation in Plasma Lipoprotein(a) Concentration. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1701-1706.	1.1	15
744	Angiotensinogen Gene Variation Associated With Variation in Blood Pressure in Aboriginal Canadians. Hypertension, 1997, 29, 1073-1077.	1.3	34
745	The pathogenesis of atherosclerosis. Clinica Chimica Acta, 1996, 246, 21-38.	0.5	94
746	Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Current Opinion in Lipidology, 1996, 7, 69-76.	1.2	389
747	Restriction isotyping of the premature termination variant of lipoprotein lipase in alberta hutterites. Clinical Biochemistry, 1996, 29, 63-66.	0.8	7
748	Genetic diagnosis of familial hypercholesterolemia in affected relatives using pedigree tracing. Clinical Biochemistry, 1996, 29, 371-377.	0.8	4
749	Retinopathy and Neuropathy Associated With Complete Apolipoprotein A-I Deficiency. American Journal of the Medical Sciences, 1996, 312, 30-33.	0.4	19
750	Genetic and Biochemical Factors Associated With Variation in Blood Pressure in a Genetic Isolate. Hypertension, 1996, 27, 308-312.	1.3	21
751	Successful Outcome in Severe Pregnancy-Associated Hyperlipemia: A Case Report and Literature Review. American Journal of the Medical Sciences, 1995, 309, 213-218.	0.4	47
752	Apolipoprotein A-I Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 2157-2164.	1.1	27
753	A Polymorphism of the Paraoxonase Gene Associated With Variation in Plasma Lipoproteins in a Genetic Isolate. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 89-95.	1.1	115
754	Multiple Genetic Determinants of Variation of Plasma Lipoproteins in Alberta Hutterites. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 861-871.	1.1	61
755	Apolipoprotein B and E Basic Amino Acid Clusters Influence Low-Density Lipoprotein Association with Lipoprotein Lipase Anchored to the Subendothelial Matrix. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1240-1247.	1.1	17
756	Genetic Variation on Chromosome 1 Associated With Variation in Body Fat Distribution in Men. Circulation, 1995, 92, 1089-1093.	1.6	47

#	Article	IF	Citations
757	Restriction Isotyping of Apolipoprotein E. Annals of Internal Medicine, 1995, 122, 68.	2.0	0
758	Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. American Journal of Cardiology, 1994, 73, 339-345.	0.7	78
759	Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. American Journal of Cardiology, 1993, 72, 171-176.	0.7	480
760	The apolipoprotein E gene and the serum low-density lipoprotein cholesterol response to dietary fiber. Metabolism: Clinical and Experimental, 1993, 42, 585-593.	1.5	39
761	Effect on Blood Lipids of Very High Intakes of Fiber in Diets Low in Saturated Fat and Cholesterol. New England Journal of Medicine, 1993, 329, 21-26.	13.9	270
762	A possible escape phenomenon of lipoprotein(a) in sustained plasma exchange. Transfusion Science, 1993, 14, 417-421.	0.6	0
763	Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia. American Journal of Cardiology, 1993, 72, 402-406.	0.7	10
764	Genetic Variation Associated with Differences in the Response of Plasma Apolipoprotein B Levels to Dietary Fibre. Clinical Science, 1993, 85, 269-275.	1.8	10
765	Molecular basis and allele specific screening of apolipoprotein CIISt. Michael. Clinical Biochemistry, 1992, 25, 309-312.	0.8	3
766	Human hepatic lipase mutations and polymorphisms. Human Mutation, 1992, 1, 320-324.	1.1	43
767	Compound heterozygosity for mutant hepatic lipase in familial hepatic lipase deficiency. Biochemical and Biophysical Research Communications, 1991, 179, 78-84.	1.0	34
768	Case Report: Heterogeneity of Aldolase B in Hereditary Fructose Intolerance. American Journal of the Medical Sciences, 1991, 302, 364-368.	0.4	5
769	Variation within intron 3 of the apolipoprotein CII gene. Nucleic Acids Research, 1991, 19, 3162-3162.	6.5	3
770	Linkage disequilibrium between DNA markers at the low-density lipoprotein receptor gene. Genetic Epidemiology, 1990, 7, 69-81.	0.6	32
771	Lipoprotein(a) and Plasminogen: Linkage Analysis. , 1990, , 129-139.		3
772	Allele Frequencies of Apolipoprotein A-I and A-II Gene Locus DNA Polymorphisms in Boston-Based Whites. Human Heredity, 1989, 39, 174-178.	0.4	6
773	Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. American Journal of Cardiology, 1989, 63, 109-112.	0.7	19
774	Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene. Genomics, 1988, 3, 230-236.	1.3	98

#	Article	IF	Citations
775	Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility. Genetic Epidemiology, 1987, 4, 163-184.	0.6	55
776	Apolipoprotein Bâ€“Gene DNA Polymorphisms Associated with Myocardial Infarction. New England Journal of Medicine, 1986, 315, 1509-1515.	13.9	282
777	Pituitary apoplexy associated with a triple bolus test. Journal of Neurosurgery, 1984, 61, 586-590.	0.9	64
778	Cross-Sectional and Prospective Associations between Abdominal Adiposity and Proinsulin Concentration. , 0, .		8
779	Targeted copy number variant identification across the neurodegenerative disease spectrum. Molecular Genetics & Genomic Medicine, 0, , .	0.6	3